北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI'AN 致:汉商集团股份有限公司 北京市嘉源律师事务所 关于汉商集团股份有限公司 2024年年度股东会的法律危见书 北京市嘉源律师事务所 关于汉商集团股份有限公司 2024 年年度股东会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 二〇二五年五月 嘉源(2025)-04-341 北京市嘉源律师事务所(以下简称"本所")接受汉商集团股份有限公司(以 下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公司法》") 《上市公司股东会规则》(以下简称"《股东会规则》")等现行有效的法律、行 政法规、部门规章、规范性文件(以下简称"法律法规")以及《汉商集团股份有 限公司章程》(以下简称"《公司章程》")的有关规定,指派本所律师对公司 2024年年度股东会(以下简称"本次股东会")进行见证,并依法出具本法律意 见书。 为出具本法律意见书,本所指派律师现场见证了本次股东会,查阅了公司提 供的与本次股东会有关的文件和资料,并进行 ...

Meeting Overview - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025 on May 12, 2025, from 15:00 to 16:00 [1][2] - The meeting was attended by key executives including the vice chairman and independent directors, facilitating interaction with investors [2] Differentiation Strategy - The company aims to maintain its competitive edge through a diversified product portfolio, including 92 pharmaceutical products across various therapeutic areas [3] - A comprehensive sales system has been established with over 400 sales personnel covering 31 provinces, reaching more than 10,000 hospitals and nearly 300,000 retail pharmacy stores [4] - The company emphasizes a specialized R&D platform to drive innovation, with ongoing clinical studies for its global Class I innovative drug projects [5][10] Medical Device Business - In 2024, the medical device segment generated revenue of approximately 82.57 million yuan, reflecting a year-on-year growth of 14.57% [7] - The product line includes absorbable medical devices, which are gaining traction in various surgical fields, contributing to sustained growth [8] R&D Investment - The total R&D expenditure for 2024 was approximately 4.51 million yuan, focusing on enhancing product lines and ensuring sustainable development [9] Financial Performance - For the first quarter of 2025, the company reported total revenue of approximately 257.42 million yuan, with net profit attributable to shareholders at approximately 2.76 million yuan [11] - The company’s exhibition business generated revenue of approximately 70.25 million yuan in 2024, showing a growth of 3.81% [12] Industry Outlook - The pharmaceutical industry is experiencing diversification and structural changes, presenting both opportunities and challenges for companies [18] - The medical device sector is witnessing accelerated domestic substitution and technological innovation, supported by favorable government policies [18] - The commercial retail sector is becoming increasingly competitive, with brands focusing on professional and differentiated strategies to meet consumer demands [19] - The exhibition industry is expected to continue its rapid growth, leveraging digital platforms and innovative approaches to enhance user experience [19]

证券代码：600774 股票简称：汉商集团 编号：2025-031 汉商集团股份有限公司 关于2024年度暨2025年第一季度业绩说明会 召开情况的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实、准确和完整承担法律责任。 汉商集团股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日 15:00-16:00 通过上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com）召 开了 2024 年度暨 2025 年第一季度业绩说明会。现将说明会情况公告如下： 1、 面对同行低价竞争，公司如何保持差异化优势？ 回复：公司将从以下几方面保持差异化优势: （1）持续赋能的产品组合。公司不仅拥有具有临床应用优势的核心产品， 同时公司持续挖掘各个产品的医用价值，以疗效巩固强化产品市场地位。公司目 前已有的在售化药、中药 92 种，涉及消化系统、呼吸系统、抗感染等多领域。 其中，核心产品主要包括消化领域产品雷贝拉唑钠肠溶片（安斯菲）、呼吸道领 域产品通窍鼻炎颗粒、医疗器械可吸收医用膜等，在各自细分领域均长期保持领 先地位，且核心产品 ...

Core Insights - The medical beauty sector experienced a slight increase of 0.53% on May 8, with a total capital outflow of 224.7 million [1] - A total of 43 stocks in the sector rose, while 21 stocks declined [1] Top Gainers - The top ten gainers in the sector included: - Aipeng Medical: +13.1% - Haochen Medical: +9.85% - Guangyunda: +9.8% - ST Jingfeng: +5.01% - ST Biological: +4.98% - Hangzhou Jiebai: +4.34% - Langzi Co.: +4.11% - Hanyu Pharmaceutical: +2.7% - Xinyaqiang: +1.57% - Dezhan Health: +1.29% [1] Top Losers - The stocks with the largest declines included: - Hanshang Group: -9.99% - Lafang Cosmetics: -6.79% - Changshan Pharmaceutical: -5.7% - ST Suwu: -4.84% - Chaohongji: -4.75% [1]

高位股盘初多数下跌，先达股份（603086）、汉商集团（600774）跌停，鸿博股份（002229）跌超 8%，大叶股份（300879）、联盛化学（301212）纷纷下挫。 ...

证券代码：600774 股票简称：汉商集团 编号：2025-030 经公司核实，公司未发现可能或已经对上市公司股票交易价格产生影响的 媒体报道或市场传闻，亦不涉及热点概念事项。 二、市场交易风险提示 公司股票于 2025 年 4 月 29 日、2025 年 4 月 30 日、2025 年 5 月 6 日已连 续 3 个交易日涨停，股价累计涨幅 30.04%，敬请广大投资者注意市场交易风险， 理性投资。 三、媒体报道、市场传闻、热点概念情况的不确定性风险 经公司自查，公司目前日常经营情况未发生重大变化。市场环境及行业政 策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩 序正常。 2025年4月30日，公司披露了《2024年年度报告》，实现归属于上市公司股 东净利润-1,458.72万元，同比下降123.83%。同日，公司披露了《2025年1季度 报告》，实现归属于上市公司股东净利润276.14万元，同比下降78.21%。具体经 营 数 据 等 信 息 请 以 公 司 于 2025 年 4 月 30 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及指定信息披露媒体 ...

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

（600774） 2024 年年度股东大会 会议文件 汉商集团股份有限公司董事会 2025 年 5 月 2024 年年度股东大会会议材料 目录 | 2024 年年度股东大会会议须知 3 | | | --- | --- | | 2024 年年度股东大会议程 4 | | | 议案一、2024 年年度报告及摘要 5 | | | 议案二、董事会 | 2024 年度工作报告 6 | | 议案三、2024 年度财务决算报告 16 | | | 议案四、监事会 2024 年度工作报告 21 | | | 议案五、独立董事 2024 年度述职报告 23 | | | 议案六、2024 年度利润分配及资本公积金转增股本议案 24 | | | 议案七、关于续聘会计师事务所的议案 25 | | | 议案八、关于续展及新增担保额度的议案 26 | | | 议案九、关于提请股东大会授权董事会办理公司以简易程序向特定对象发行股 | | | 票相关事宜的议案 30 | | 2 2024 年年度股东大会会议材料 汉商集团股份有限公司 2024 年年度股东大会会议须知 为维护投资者的合法权益，确保汉商集团股份有限公司（以下简称"公司"） 2024 ...

证券代码：600774 股票简称：汉商集团 编号：2025-029 汉商集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 股票交易连续3个交易日内（2025年4月28日、2025年4月29日、2025年4月 30日）收盘价格涨幅偏离值累计超过20％。根据《上海证券交易所交易规则》 的相关规定，公司股票交易属于异常波动情况。 二、公司关注并核实的相关情况 （一）生产经营情况。 经公司自查，公司目前日常经营情况未发生重大变化。市场环境及行业政 策未发生重大调整，生产成本和销售等情况未出现大幅波动，内部生产经营秩 序正常。 2025年4月30日，公司披露了《2024年年度报告》《2025年1季度报告》。 （二）重大事项情况。 经公司自查，并向公司控股股东书面函证核实，截至本公告日，除已披露 的前期重大资产重组事项外，不存在正在筹划涉及上市公司的其他重大资产重 组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、破产重整、 重大业务合作、引进战略投资者等重大事项。在公司本次 ...

卓尔控股有限公司 关于股票交易异常波动有关情况的回函 汉商集团股份有限公司: 贵公司《关于重大事项的询证函》已收悉。本公司作为贵公司控股股东, 经核查,现将有关事项回函如下: 1、截至本函回复之日,除前期已披露的重大资产重组事项外,本公司及一 致行动人未筹划涉及上市公司的其他重大资产重组、股份发行、收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大 业务合作、引进战略投资者等重大事项。 2、在贵公司本次股票交易异常波动期间,本公司及一致行动人不存在买卖 汉商集团股票的情况。 3、在贵公司本次股票交易异常波动期间,本公司及一致行动人未出现其他 可能对上市公司股价产生较大影响的重大事件。 4、在贵公司本次股票交易异常波动期间,本公司及一致行动人不存在其他 应披露而未披露的事项。 特此回函。 ...